October 2nd 2025
October 1st 2025
Patient response focused on perceived vision-related quality of life outcomes, investigators said
September 24th 2025
EyeArt uses artificial intelligence for autonomous detection of vision-threatening diabetic retinopathy
September 22nd 2025
The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO
September 17th 2025
Alteogen received a positive CHMP opinion for EYLUXVI in July 2025
EURETINA leadership welcome record-breaking number of attendees
This year's EURETINA meeting boasts a crowd of 10,000 attendees, including delegates, industry leaders, and young retina specialists.
EURETINA grants Prithvi Ramtohul, MD, 2025 Ramin Tadayoni Award
Dr Ramtohul's research uses electrophysiologic testing to study the retinal ganglion cells
EMA grants Orphan designations to MCO-010 across 5 categories of retinal dystrophies
The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).
EURETINA industry previews: Beacon Therapeutics, Nanoscope Therapeutics and Valitor
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
Ashvattha Therapeutics, Clearside Biomedical, ZEISS preview EURETINA presentations
Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings
Progression rates vary in subtypes of geographic atrophy lesions
An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration
The Eye Care Network's clinical advisors will present at EURETINA
Where to find members of our editorial board at this year's European Society of Retina Specialists Congress
What to expect at this year's European Society of Retina Specialists (EURETINA) Congress
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
Québec announces faricimab (Vabysmo, Roche) will be funded for macular oedema secondary to RVO
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
Patient outcomes in retinoblastoma impacted by parents' interventional delays
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
Recap: The future of imaging is out of this world
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
Australian biotech firm Mirugen secures major funding for cell reprogramming therapy
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Sandoz will license Lupin's ranibizumab biosimilar in Europe, other select regions
Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries
German case study illustrates systemic presentation of tubulointerstitial nephritis and uveitis
An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation
Helping patients navigate the unsolved mysteries of genetic testing
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases
NICE announces UK approval of idebenone for treatment of Leber hereditary optic neuropathy
In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment
A realistic view of diabetes remission: GLP-1 therapies and the future of diabetic retinopathy
GLP-1 therapies could impact long-term outcomes in diabetic retinopathy
Managing and monitoring the global burden of retinoblastoma
Enhanced screenings and a unified registry could save vision and lives
Opus Genetics, Global RDH12 Alliance announce new collaboration
The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight
Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition
The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening
Exonate announces CLEAR-DE trial for EXN407
Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy
Biomarkers of microvascular retinal perfusion indicating coronary heart disease
Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography
Alteogen receives positive CHMP opinion for aflibercept biosimilar EYLUXVI
According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”
Fungal infection and vision impact in patients with diabetic eye disease
Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.